Search | SciELO

Need help?

Add field +

Search history

No documents were found for your search

Results: 13

au:"Sato, Douglas Kazutoshi"

Filters

Collection

All
Brazil

13

Journal + Options

All
Arquivos de Neuro-Psiquiatria

12
Jornal de Pediatria

1

Language

All
Portuguese

1

Publication Year + Options

All
2017

3
2023

3
2014

2
2016

2
2018

1
2020

1
2021

1

SciELO Thematic Areas

All
Health Sciences

13

WoS Subject Categories + Options

All
Neurosciences

12
Psychiatry

12
Pediatrics

1

WoS Citation Index

All
Science Citation Index Expanded

13

Citables and non citables + Options

All
Citable

8
Non citable

5

Type of Literature + Options

All
Article

5
Editorial

4
Review article

3
Other

1

Order by

Page of 1 Next

Select this page

Print | Send to email | Export |

Facebook
Twitter
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

0 Selected itens

List all
Erase all

Reshaping neuroimmunology: diagnosis and treatment in the era of precision medicine
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

dos Passos, Giordani Rodrigues

; Adoni, Tarso

; Mendes, Maria Fernanda

; Sato, Douglas Kazutoshi

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

dec 2023, Volume 81 N. 12 Pages 1125 - 1133

Abstract: En Pt | Text: En Pt | PDF: En | PDF: Pt

Abstract Precision medicine has revolutionized the field of neuroimmunology, with innovative approaches that characterize diseases based on their biology, deeper understanding of the factors leading to heterogeneity within the same disease, development of targeted therapies, and strategies to tailor therapies to each patient. This review explores the impact of precision medicine on various neuroimmunological conditions, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), optic neuritis, autoimmune encephalitis, and immune-mediated neuropathies. We discuss advances in disease subtyping, recognition of novel entities, promising biomarkers, and the development of more selective monoclonal antibodies and cutting-edge synthetic cell-based immunotherapies in neuroimmunological disorders. In addition, we analyze the challenges related to affordability and equity in the implementation of these emerging technologies, especially in situations with limited resources.

Resumo A medicina de precisão está revolucionando o campo da neuroimunologia, com uma abordagem inovadora caracterizada pela classificação de doenças com base em sua biologia, compreensão mais profunda dos fatores que levam à heterogeneidade dentro da mesma doença, desenvolvimento de terapias com alvos específicos e estratégias para adaptar as terapias a cada paciente. Esta revisão explora o impacto da medicina de precisão em várias condições neuroimunológicas, incluindo esclerose múltipla (EM), distúrbio do espectro da neuromielite óptica (NMOSD), doença associada ao anticorpo anti-glicoproteína da mielina do oligodendrócito (MOGAD), neurites ópticas, encefalites autoimunes e neuropatias imunomediadas. Discutimos avanços na subclassificação de doenças, reconhecimento de novas entidades, biomarcadores promissores e desenvolvimento de anticorpos monoclonais mais seletivos e imunoterapias de ponta baseadas em células sintéticas para as condições acima. Além disso, analisamos os desafios relacionados com acessibilidade e equidade na implementação dessas tecnologias emergentes, especialmente em ambientes com recursos limitados.

https://doi.org/10.1055/s-0043-1777752

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Fragoso, Diego Cardoso

; Salles, Luana Michelli Oliveira de Paula

; Pereira, Samira Luisa Apóstolos

; Callegaro, Dagoberto

; Sato, Douglas Kazutoshi

; Rimkus, Carolina de Medeiros

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

jun 2023, Volume 81 N. 6 Pages 533 - 543

Abstract: En Pt | Text: En Pt | PDF: En | PDF: Pt

Abstract Background There is clinical and radiological overlap among demyelinating diseases. However, their pathophysiological mechanisms are different and carry distinct prognoses and treatment demands. Objective To investigate magnetic resonance imaging (MRI) features of patients with myelin-oligodendrocyte glycoprotein associated disease (MOGAD), antibody against aquaporin-4(AQP-4)-immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), and double-seronegative patients. Methods A cross-sectional retrospective study was performed to analyze the topography and morphology of central nervous system (CNS) lesions. Two neuroradiologists consensually analyzed the brain, orbit, and spinal cord images. Results In total, 68 patients were enrolled in the study (25 with AQP4-IgG-positive NMOSD, 28 with MOGAD, and 15 double-seronegative patients). There were differences in clinical presentation among the groups. The MOGAD group had less brain involvement (39.2%) than the NMOSD group (p = 0.002), mostly in the subcortical/juxtacortical, the midbrain, the middle cerebellar peduncle, and the cerebellum. Double-seronegative patients had more brain involvement (80%) with larger and tumefactive lesion morphology. In addition, double-seronegative patients showed the longest optic neuritis (p = 0.006), which was more prevalent in the intracranial optic nerve compartment. AQP4-IgG-positive NMOSD optic neuritis had a predominant optic-chiasm location, and brain lesions mainly affected hypothalamic regions and the postrema area (MOGAD versus AQP4-IgG-positive NMOSD, p= 0 .013). Furthermore, this group had more spinal cord lesions (78.3%), and bright spotty lesions were a paramount finding to differentiate it from MOGAD (p = 0.003). Conclusion The pooled analysis of lesion topography, morphology, and signal intensity provides critical information to help clinicians form a timely differential diagnosis.

Resumo Antecedentes Há sobreposição clínica e radiológica entre as doenças desmielinizantes. No entanto, seus mecanismos fisiopatológicos são diferentes e apresentam prognósticos e demandas de tratamento distintos. Objetivo Investigar as características de imagens de RM dos pacientes com doença associada à glicoproteína de oligodendrócito de mielina (MOGAD), a doenças do espectro da neuromielite óptica positivas para antiaquaporina-4 imunoglobulina G (AQP4-IgG NMOSD), e pacientes duplamente soronegativos. Métodos Estudo retrospectivo e transversal para analisar as características e frequência das lesões do sistema nervoso central (SNC). Dois neurorradiologistas avaliaram consensualmente as imagens do cérebro, das órbitas e da medula espinhal. Resultados Ao todo, foram incluídos 68 pacientes(25 com AQP4-IgG NMOSD, 28 com MOGAD e 15 duplo-soronegativos). Há diferenças na apresentação clínica entre os grupos. O grupo MOGAD demonstrou menor frequência de comprometimento do cérebro (39.2%) comparado com o AQP4-IgG NMOSD (p = 0.002), com predomínio da distribuição das lesões nas regiões subcortical/justacortical, mesencéfalo, pedúnculos cerebelares médios e cerebelo. O grupo duplo-soronegativo demonstrou maior frequência de comprometimento do cérebro (80%), com lesões de maiores dimensões e com morfologia tumefeita, além de neurite óptica com maior extensão (p = 0.006). O grupo AQP4-IgG NMOSD demonstrou neurite óptica com predomínio na região óptico-quiasmática e as lesões encefálicas acometeram predominantemente as regiões hipotalâmica e área postrema (MOGAD versus AQP4-IgG NMOSD p = 0.013). Além disso, foram observadas mais lesões na medula espinhal (78.3%) e a presença da “bright spotty lesion” foi um achado primordial para a sua diferenciação com os pacientes MOGAD (p = 0.003). Conclusão A análise pormenorizada das características das lesões por RM dos pacientes com doenças desmielinizantes imunomediadas fornece informações fundamentais que auxiliam os médicos no diagnóstico diferencial em um momento oportuno.

https://doi.org/10.1055/s-0043-1768669

Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Paolilo, Renata Barbosa

; Paz, José Albino da

; Apóstolos-Pereira, Samira Luisa

; Rimkus, Carolina de Medeiros

; Callegaro, Dagoberto

; Sato, Douglas Kazutoshi

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

2023, Volume 81 N. 2 Pages 201 - 211

Abstract: En Pt | Text: En Pt | PDF: En | PDF: Pt

Abstract Neuromyelitis optica spectrum disorder (NMOSD) is a rare and severe inflammatory disorder of the central nervous system (CNS). It is strongly associated with anti-aquaporin 4 antibodies (AQP4-IgG), and it mainly affects young women from non-white ethnicities. However, ~ 5 to 10% of all cases have onset during childhood. Children and adolescents share the same clinical, radiologic, and laboratory presentation as adults. Thus, the same NMOSD diagnostic criteria are also applied to pediatric-onset patients, but data on NMOSD in this population is still scarce. In seronegative pediatric patients, there is a high frequency of the antibody against myelin oligodendrocyte glycoprotein (MOG-IgG) indicating another disease group, but the clinical distinction between these two diseases may be challenging. Three drugs (eculizumab, satralizumab, and inebilizumab) have been recently approved for the treatment of adult patients with AQP4-IgG-positive NMOSD. Only satralizumab has recruited adolescents in one of the two pivotal clinical trials. Additional clinical trials in pediatric NMOSD are urgently required to evaluate the safety and efficacy of these drugs in this population.

Resumo O espectro da neuromielite óptica (ENMO) é uma rara e grave doença inflamatória do sistema nervoso central (SNC), fortemente associada ao anticorpo anti-aquaporina 4 (AQP4-IgG) e que afeta preferencialmente mulheres jovens de etnias não-caucasianas. No entanto, aproximadamente de 5 a 10% de todos os casos se iniciam na infância. Crianças e adolescentes compartilham as mesmas características clínicas, radiológicas e laboratoriais dos adultos. Além disso, o mesmo critério diagnóstico de ENMO é aplicado para pacientes com início na infância. No entanto, dados da população pediátrica são escassos. Em pacientes pediátricos soronegativos, existe uma alta frequência de positividade ao anticorpo contra a glicoproteína na mielina do oligodendrócito (MOG-IgG), indicando outra patologia; porém, a distinção clínica entre as duas doenças é desafiadora. Três medicações (eculizumabe, inebilizumabe e satralizumabe) foram recentemente aprovadas para pacientes adultos com AQP4-IgG. Apenas um dos ensaios pivotais do satralizumabe recrutou adolescentes. Novos ensaios clínicos em pacientes pediátricos com ENMO são necessários para avaliar a segurança e eficácia destas drogas nesta população.

https://doi.org/10.1055/s-0043-1761432

Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

GOMES, Ana Beatriz Ayroza Galvão Ribeiro

; PITOMBEIRA, Milena Sales

; SATO, Douglas Kazutoshi

; CALLEGARO, Dagoberto

; APÓSTOLOS-PEREIRA, Samira Luisa

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

mar 2021, Volume 79 N. 3 Pages 229 - 232

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

RESUMO Introdução: A azatioprina é um tratamento comum de primeira linha para os transtornos do espectro neuromielite óptica (NMOSD). Objetivo: Este estudo visou determinar a segurança do tratamento a longo prazo (>10 anos) da NMOSD com a azatioprina. Métodos: Foi realizada revisão retrospectiva de todos os prontuários de pacientes que preenchiam critérios de NMOSD de acordo com o “International Consensus Diagnostic Criteria for NMOSD” de 2015 em uso de azatioprina por ao menos 10 anos matriculados no ambulatório de Doenças Desmielinizantes do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Resultados: De 375 pacientes avaliados, 19 preencheram critérios de inclusão para análise. A mediana de idade foi de 44 anos (variância=28-61); os pacientes eram predominantemente do sexo feminino (17/19) e AQP4-IgG soropositivos (18/19). A mediana do tempo de duração de doença foi 11,9 anos (variância=10,0-23,8), a mediana da taxa anualizada de surtos pré e pós-tratamento foi de 1 (variância=0,1-2) e 0,1 (variância=0-0,35), p=0,09. Três pacientes (15,7%) apresentaram registro de eventos adversos durante o seguimento: deficiência crônica de vitamina B12, tuberculose pulmonar e câncer de mama. Conclusão: A azatioprina provavelmente pode ser considerada segura para o tratamento a longo prazo (>10 anos) da NMOSD, porém vigilância contínua de neoplasias e infecções é necessária.

ABSTRACT Background: Azathioprine is a common first-line therapy for neuromyelitis optica spectrum disorder (NMOSD). Objective: The aim of this study was to determine whether long-term treatment (>10 years) with azathioprine is safe in NMOSD. Methods: We conducted a retrospective medical record review of all patients at the School of Medicine of the University of São Paulo (São Paulo, Brazil) who fulfilled the 2015 international consensus diagnostic criteria for NMOSD and were treated with azathioprine for at least 10 years. Results: Out of 375 patients assessed for eligibility, 19 were included in this analysis. These patients’ median age was 44 years (range=28-61); they were mostly female (17/19) and AQP4-IgG seropositive (18/19). The median disease duration was 15 years (range=10-39) and most patients presented a relapsing clinical course (84.2%). The median duration of treatment was 11.9 years (range=10.0-23.8). The median annualized relapse rates (ARR) pre- and post-treatment with azathioprine were 1 (range=0.1-2) and 0.1 (range=0-0.35); p=0.09. Three patients (15.7%) had records of adverse events during the follow-up, which consisted of chronic B12 vitamin deficiency, pulmonary tuberculosis and breast cancer. Conclusion: Azathioprine may be considered a safe agent for long-term treatment (>10 years) of NMOSD, but continuous vigilance for infections and malignancies is required.

https://doi.org/10.1590/0004-282x-anp-2020-0041 434 downloads

Viral encephalitis: a practical review on diagnostic approach and treatment
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Costa, Bruna Klein da

; Sato, Douglas Kazutoshi

Jornal de Pediatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

mar 2020, Volume 96 Suppl. 1 Pages 12 - 19

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

Resumo Objetivos Revisar os critérios diagnósticos para encefalite e encefalopatia de etiologia infecciosa presumida, assim como a investigação diagnóstica para encefalite viral e suas abordagens terapêuticas. Além disso, pretendemos resumir tópicos relevantes sobre os vírus específicos frequentemente encontrados no Brasil. Fonte de dados Pesquisa bibliográfica feita nos bancos de dados Pubmed/Medline utilizando as seguintes palavras-chave: “viral”, “encephalitis”, “child” ou “adolescents”, limitando os artigos a estudos em humanos e escritos em inglês. Resumo dos dados A encefalite viral é a causa mais comum de encefalite e é responsável por altas taxas de morbidade, sequelas neurológicas permanentes e, de acordo com o vírus, altas taxas de mortalidade. As etiologias mais comuns são herpes vírus 1 e 2 (HSV-1 e HSV-2), enterovírus não pólio e arbovírus (no Brasil, Dengue, Zika e Chikungunya). Outras etiologias relevantes são a influenza sazonal, o citomegalovírus (CMV), o vírus Epstein-Barr (EBV), o herpes vírus humano 6 (HHV-6) e o sarampo reemergente. Conclusão Dados clínicos, resultados laboratoriais e de neuroimagem apoiam o diagnóstico de encefalite e a etiologia viral específica. Para aumentar a probabilidade de confirmação etiológica, é importante conhecer a melhor abordagem para coletar amostras e escolher a melhor técnica de identificação para cada vírus. O diagnóstico diferencial de encefalite viral inclui outras infecções e distúrbios inflamatórios do sistema nervoso central imunomediados.

Abstract Objectives To review the diagnostic criteria for encephalitis and encephalopathy of presumed infectious etiology, as well as the diagnostic workup for viral encephalitis and its treatment approaches. The authors also intended to summarize relevant information on specific viruses frequently found in Brazil. Source of data Literature search on Pubmed/MEDLINE using the following keywords: “viral”, “encephalitis”, “child”, or “adolescents”, filtering for articles on humans and in English. Summary of data Viral encephalitis is the most common cause of encephalitis and is responsible for high rates of morbidity, permanent neurologic sequelae, and according to the virus, may have high mortality rates. The most common etiologies are herpesviruses 1 and 2 (HSV-1 and HSV-2), non-polio enterovirus, and arboviruses (in Brazil, dengue, Zika, and chikungunya). Other relevant etiologies are seasonal influenza, cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and the re-emergent measles. Conclusion Clinical data, laboratory results, and neuroimaging findings support the diagnosis of encephalitis and the specific viral etiology. To increase the likelihood of etiologic confirmation, it is important to know the best approach to collecting samples and to choose the best identification technique for each virus. The differential diagnosis of viral encephalitis includes other infections and immune-mediated inflammatory central nervous system disorders.

https://doi.org/10.1016/j.jped.2019.07.006 17137 downloads

Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Marques, Vanessa Daccach

; Passos, Giordani Rodrigues dos

; Mendes, Maria Fernanda

; Callegaro, Dagoberto

; Lana-Peixoto, Marco Aurélio

; Comini-Frota, Elizabeth Regina

; Vasconcelos, Cláudia Cristina Ferreira

; Sato, Douglas Kazutoshi

; Ferreira, Maria Lúcia Brito

; Parolin, Mônica Koncke Fiuza

; Damasceno, Alfredo

; Grzesiuk, Anderson Kuntz

; Muniz, André

; Matta, André Palma da Cunha

; Oliveira, Bianca Etelvina Santos de

; Tauil, Carlos Bernardo

; Maciel, Damacio Ramón Kaimen

; Diniz, Denise Sisteroli

; Corrêa, Eber Castro

; Coronetti, Fernando

; Jorge, Frederico M. H.

; Sato, Henry Koiti

; Gonçalves, Marcus Vinícius Magno

; Sousa, Nise Alessandra de C.

; Nascimento, Osvaldo J. M.

; Gama, Paulo Diniz da

; Domingues, Renan

; Simm, Renata Faria

; Thomaz, Rodrigo Barbosa

; Morales, Rogério de Rizo

; Dias, Ronaldo Maciel

; Apóstolos-Pereira, Samira dos

; Machado, Suzana Costa Nunes

; Junqueira, Thiago de Faria

; Becker, Jefferson

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

aug 2018, Volume 76 N. 8 Pages 539 - 554

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

RESUMO O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e personalizados, mas a escolha e o manejo das terapias modificadoras da doença (TMDs) tem se tornado cada vez mais complexos. Neste contexto, especialistas do Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla e do Departamento Científico de Neuroimunologia da Academia Brasileira de Neurologia reuniram-se para estabelecer este Consenso Brasileiro para o Tratamento da EM, baseados no entendimento de que neurologistas devem ter a possibilidade de prescrever TMDs para EM de acordo com o que é melhor para cada paciente, com base em evidências e práticas atualizadas. Por meio deste documento, propomos recomendações práticas para o tratamento da EM, com foco principal na escolha e no manejo das TMDs, e revisamos os argumentos que embasam as estratégias de tratamento na EM.

ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.

https://doi.org/10.1590/0004-282x20180078 8891 downloads

Isolated rhombencephalitis with good clinical recovery
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Costa, Bruna Klein da

; Oliveira, Bruno Samuel Fraiman de

; Becker, Jefferson

; Sato, Douglas Kazutoshi

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

oct 2017, Volume 75 N. 10 Pages 757 - 757

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/0004-282x20170133 1074 downloads

MOG-IgG associated optic neuritis is not multiple sclerosis
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Costa, Bruna Klein da

; Passos, Giordani Rodrigues dos

; Becker, Jefferson

; Sato, Douglas Kazutoshi

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

oct 2017, Volume 75 N. 10 Pages 687 - 691

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

RESUMO Autoanticorpos contra a glicoproteína da mielina do oligodendrócito (MOG-IgG) têm sido descritos em pacientes com neurite óptica (NO) isolada, entre outras doenças inflamatórias do sistema nervoso central. Comparamos os nossos pacientes com NO MOG-IgG positivos com pacientes com NO associada a esclerose múltipla (EM). Materias e métodos: De um total de 38 pacientes com neuropatia óptica, seis foram MOG-IgG positivos e oito preencheram critérios diagnósticos para EM. Todos os pacientes com EM foram negativos para MOG-IgG (ensaio baseado em células). Quando comparados ao grupo com EM, os pacientes MOG-IgG positivos apresentam idade mais avançada (mediana de 47 anos) e tiveram uma frequência maior de NO bilateral e/ou recorrente. Houve predomínio masculino (relação 2:1). A ressonância magnética de encéfalo de todos os pacientes MOG-IgG positivos foi normal ou demonstrou apenas lesões inespecíficas em T2. Conclusão: Nossos achados sugerem que o MOG-IgG é um biomarcador de doença desmielinizante diferente da EM.

ABSTRACT Autoantibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been reported in patients with inflammatory central nervous system disorders including isolated optic neuritis (ON). We compared our MOG-IgG ON patients with multiple sclerosis (MS) patients presenting with ON. Methods and results: Among the total of 38 patients with optic neuropathies, six patients with isolated ON were MOG-IgG positive and eight patients with ON fulfilled the diagnostic criteria for MS. All MS patients were negative for MOG-IgG using a cell-based assay. When compared with the MS group, the MOG-IgG patients were older (mean 47 years), more frequently male (ratio 2:1) and had a higher frequency of bilateral and/or recurrent ON. The brain magnetic resonance imaging of all MOG-IgG positive patients was normal or had only unspecific white matter T2 lesions. Conclusion: These findings suggest that MOG-IgG is a biomarker of an inflammatory demyelinating CNS disease distinct from MS.

https://doi.org/10.1590/0004-282x20170121 4155 downloads

Quality of life goes beyond the medical priorities in multiple sclerosis: assessing the impact of social support network
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Sato, Douglas Kazutoshi

; Souza, Renata Brant de

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

may 2017, Volume 75 N. 5 Pages 263 - 264

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/0004-282x20170056 1564 downloads

10.

Sometimes less is more in multiple sclerosis drug switching
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Costa, Bruna Klein da

; Sato, Douglas Kazutoshi

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

aug 2016, Volume 74 N. 8 Pages 605 - 606

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/0004-282X20160104 1607 downloads

11.

Time to target brain atrophy and neurodegeneration in multiple sclerosis
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Costa, Bruna Klein da

; Sato, Douglas Kazutoshi

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

mar 2016, Volume 74 N. 3 Pages 181 - 182

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/0004-282X20160028 1785 downloads

12.

Oral fingolimod to treat multiple sclerosis: see your cardiologist first
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Sato, Douglas Kazutoshi

; Callegaro, Dagoberto

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

sep 2014, Volume 72 N. 9 Pages 651 - 652

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/0004-282X20140171 1744 downloads

13.

Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Sato, Douglas Kazutoshi

; Callegaro, Dagoberto

; Lana-Peixoto, Marco Aurélio

; Nakashima, Ichiro

; Fujihara, Kazuo

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

jun 2014, Volume 72 N. 6 Pages 445 - 450

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

O espectro da neuromielite óptica (NMOSD) é caracterizado por ataques graves de neurite óptica e mielite. Anticorpos séricos contra a aquaporina-4 (AQP4) são usualmente presentes nestes pacientes. Entretanto, alguns pacientes com NMOSD são seronegativos mesmo com testes repetidos em amostras obtidas durante ataques usando métodos altamente sensíveis baseados em células. O diagnóstico diferencial não é restrito à esclerose múltipla e inclui muitas doenças que podem produzir mielite longitudinalmente extensa e/ou neurite óptica. São abordadas as características clínicas, de imagem e de laboratório que podem ser úteis no diagnóstico, as diferenças entre os pacientes positivos para o anticorpo anti-AQP4 e os negativos, incluindo as características dos pacientes com NMOSD que possuem anticorpos contra a glicoproteína associada ao oligodendrócito.

Neuromyelitis optica spectrum disorders (NMOSD) are characterized by severe optic neuritis and/or longitudinally extensive transverse myelitis, and some brain lesions are also unique to NMOSD. Serum autoantibodies against aquaporin-4 (AQP4) are detected in most cases of NMOSD. However, some patients with NMOSD remain seronegative despite repetitive testing during attacks with highly sensitive cell-based assays. The differential diagnosis of NMOSD is not restricted to multiple sclerosis and it includes many diseases that can produce longitudinally extensive myelitis and/or optic neuritis. We review the clinical features, imaging, and laboratory findings that can be helpful on the diagnostic work-up, discuss the differences between AQP4 antibody positive and negative patients with NMOSD, including features of NMOSD with antibodies against myelin oligodendrocyte glycoprotein.

https://doi.org/10.1590/0004-282X20140032 11160 downloads Cited 1 time in SciELO

Showing

itens per page

Page of 1 Next

Select one or more results

All Alphabetic

Results

Comparative chart Download CSV

Statistics of

Send result

To*

Use ; (semicolon) to insert more emails.

Send to email

This page

Selected records

All references (max. 300)

Your email

Subject

Comments

Export format:

RIS (for EndNote, ProCite, Reference Manager, RefWorks, Citavi, etc.)

BibTeX

Citation

CSV (for Excel, etc)

Export:

This page

Selected itens

All references (max. 2000)

Sem resultados

No documents were found for your search

Glossary and search help

You can enrich your search in a very simple way. Use the search indexes combined with the connectors (AND or OR) and specify more your search.

For example, if you want to search for articles about
cases of dengue in Brasil in 2015, use:
ti:dengue and publication_year:2015 and aff_country:Brasil

See below the complete list of search indexes that can be used:

Index code	Element
ti	article title
au	author
kw	article keywords
subject	subject (title words, abstract and keywords)
ab	abstract
ta	journal short title (e.g. Cad. Saúde Pública)
journal_title	journal full title (e.g. Cadernos de Saúde Pública)
la	publication language code (e.g. pt - Portuguese, es - Spanish)
type	document type
pid	publication identifier
publication_year	publication year of publication
sponsor	sponsor
aff_country	country code of the author's affiliation
aff_institution	author affiliation institution
volume	article volume
issue	article issue
elocation	elocation
doi	DOI number
issn	journal ISSN
in	SciELO colection code (e.g. scl - Brasil, col - Colômbia)
use_license	article usage license code

SciELO - Scientific Electronic Library Online
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil
Email: scielo@scielo.org

All the contents of this site www.scielo.br, except where otherwise noted, is licensed under a Creative Commons Attribution License.
more »